pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
354
stories
17d
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
biospace
18d
Tortugas’ schizophrenia drug proves worth in phase 2 Hansoh trial in China
fiercebiotech
18d
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
21d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
21d
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
21d
Ono pays Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya shot
endpoints
21d
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
21d
STAT+: Roche goes beyond licensing in deal with Chinese biotech
stat
22d
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
22d
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
22d
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
22d
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
23d
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
23d
5 biggest venture capital raises of Q3 2026
biospace
23d
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
fiercebiotech
23d
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
23d
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
24d
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
24d
Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears
endpoints
24d
Significant stock movers of September: Viking soars, Longeveron slides
biospace
25d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
25d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
27d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
27d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
28d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
28d
United Therapeutics' legal victory; BMS' Camzyos approved for kids
endpoints
28d
BMS reports liver injury events in lung disease program, with key readout near
biospace
29d
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
29d
Patient death raises liver questions ahead of Bristol Myers readout
endpoints
29d
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
← prev
page 3 of 12
next →
